Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Neurogastroenterology and Motility|September 30, 2024
Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high-resolution manometry studiesStefano Kayali, Francesco Calabrese, Andrea Pasta, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 18, 2024
Diagnostic delay in achalasiaAndrea Pasta, Francesco Calabrese, Andrea Ghezzi, et al.
European Journal of Gastroenterology & Hepatology|August 13, 2025
Eosinophilic esophagitis is the leading cause of dysphagia in an outpatient settingManuele Furnari, Francesco Calabrese, Andrea Pasta, et al.
The American Journal of Gastroenterology|December 10, 2009
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapyEdoardo Savarino, Radu Tutuian, Patrizia Zentilin, et al.
World Journal of Gastroenterology|December 22, 2023
Albumin-bilirubin score in non-malignant liver diseases should be properly validatedAndrea Pasta, Francesco Calabrese, Maria Corina Plaz Torres, et al.
European Journal of Clinical Investigation|April 16, 2020
Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver diseaseEdoardo G Giannini, Costanza De Maria, Mattia Crespi, et al.
Expert Opinion on Drug Metabolism & Toxicology|July 19, 2016
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerationsEdoardo Savarino, Irene Martinucci, Manuele Furnari, et al.
Clinical and Experimental Gastroenterology|April 30, 2020
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging DataElisa Marabotto, Sebastiano Ziola, Vincenzo Savarino, et al.
Diseases (Basel, Switzerland)|November 26, 2024
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn's Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort StudiesAndrea Pasta, Francesco Calabrese, Elisa Marabotto, et al.
Clinical and Translational Gastroenterology|July 18, 2020
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort StudyBrigida Barberio, Fabiana Zingone, Renata D'Incà, et al.
Pageof 11